Ligand Pharmaceuticals (LGND) closed at $308.79 on November 13, 2026, down 2.4% from the previous close, on volume of 116,466 shares (30-day average 213,011).
Data as of November 13, 2026.
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Thu, 12-Nov 9:21 AM ET)
Barclays Sticks to Their Buy Rating for Ligand Pharma (LGND)
TipRanks (Wed, 11-Nov 4:15 AM ET)
Ligand Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 29-Oct 7:00 AM ET)
Ligand to Participate in November Investor Conferences
Globe Newswire (Tue, 27-Oct 4:01 PM ET)
Ligand to Host Investor Day on December 8, 2026
Globe Newswire (Thu, 22-Oct 4:01 PM ET)
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
Globe Newswire (Thu, 15-Oct 7:00 AM ET)
Globe Newswire (Thu, 24-Sep 7:00 AM ET)
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea
Business Wire (Tue, 22-Sep 9:02 AM ET)
Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
PRNewswire (Tue, 22-Sep 9:01 AM ET)
Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea from Sydnexis for $23 Million
Globe Newswire (Tue, 22-Sep 7:00 AM ET)
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ligand Pharmaceuticals trades on the NASDAQ stock market under the symbol LGND.
As of November 13, 2026, LGND stock price declined to $308.79 with 116,466 million shares trading.
LGND has a beta of 0.69, meaning it tends to be less sensitive to market movements. LGND has a correlation of 0.07 to the broad based SPY ETF.
LGND has a market cap of $6.18 billion. This is considered a Mid Cap stock.
Last quarter Ligand Pharmaceuticals reported $79 million in Revenue and $2.67 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.52.
In the last 3 years, LGND traded as high as $326.63 and as low as $55.02.
The top ETF exchange traded funds that LGND belongs to (by Net Assets): IJR, VTI, IWM, VB, VXF.
LGND has outperformed the market in the last year with a return of +50.2%, while the SPY ETF gained +11.5%. In the last 3 month period, LGND beat the market returning +5.3%, while SPY returned -2.1%. However, in the most recent 2 weeks LGND has underperformed the stock market by returning -2.7%, while SPY returned -1.9%.
LGND support price is $307.82 and resistance is $324.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LGND shares will trade within this expected range on the day.
